Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.J&J plans to change how it pays out discounts to 340B-eligible drugs, causing concerns for hospitals and the government. A report by the HHS' Office of Inspector General found that 1 in 4 for-profit nursing homes are not complying with infection control staffing rules due to challenges in hiring and retaining qualified personnel. Steward Health is set to close two Ohio hospitals, with a Pennsylvania facility at risk, sparking criticism from a nurse union leader. Organizations can benefit from AI with effective risk management strategies, and online tools are being used to address gaps in mental healthcare. Healthcare Dive provides insights into healthcare venture trends and offers resources on topics like combatting burnout in healthcare and using AI to improve patient records. The publication covers a range of healthcare topics including health IT, policy & regulation, insurance, and more for industry professionals.The FDA seeks feedback on predetermined change control plans for medical devices. Roche plans to increase global laboratory capacity for mpox testing due to a public health emergency. Defibtech recalls a chest compression device linked to patient death. Stryker acquires Vertos Medical to add back pain treatment to its offerings. Getinge to buy Paragonix organ-preserving technology for up to $477 million. Medtech professionals can use code MTDIVE25 for a discount at Devicetalks West conference. Companies are investing in training for a human-centered sales approach in healthcare. Other news includes missed warnings about mpox, stem cell therapy for diabetes, Neuralink's successful trial implant, and more. Medtech Dive covers medical devices, diagnostics, digital health, regulation, M&A, and other industry trends.Tome Biosciences, a startup that had raised over $200 million in venture funding, is laying off over 100 employees. Biotech IPOs are essential for the industry's growth, with companies like MBX Biosciences planning to go public. Regeneron has gained European approval for a bispecific lymphoma drug. The industry is shifting towards more patient-centric commercialization strategies, with companies like Pfizer and Lilly breaking into the direct-to-consumer market. Build-to-buy deals, where pharmaceutical companies have the option to acquire a startup's assets later, are becoming more popular. Overall, the biopharma industry is evolving rapidly, with new drugs gaining approval and companies adapting to new strategies to reach patients and investors.A deadlier strain of mpox has been confirmed in Thailand, with a higher death rate compared to previous outbreaks. The World Health Organization has launched a response plan, but vaccines have not yet been approved. The Democratic Republic of Congo, where the outbreak originated, has not received any vaccines. Siga Therapeutics' antiviral treatment suffered a setback in clinical trials but may still be effective against the virus. Pharmas continue to face legal challenges as drug prices for Medicare's negotiation program have been published. Despite disappointing results, Siga Therapeutics remains hopeful about their drug's potential. The article also highlights upcoming events and editor's picks in the pharmaceutical industry.